** A Curtain Raiser for Prevention at IAS 2019
------------------------------------------------------------
July 18, 2019

Dear Advocate,

IAS 2019 (www.ias2019.org) is just ahead, July 21-24 in Mexico City. To help you prepare, read on for a round-up of research and happenings you won’t want to miss, a roadmap to guide you to sessions where HIV prevention is center stage, and how to follow on-site or from afar.

This year’s conference will feature data from late-breakers on highly anticipated research including:

* Data on the first-ever human trial of a new PrEP implant ([link removed])

* Analysis of the need to integrate HIV prevention with sexual & reproductive health in light of the ECHO study results ([link removed])

* Updates from the Discover trial of F/TAF for PrEP ([link removed])

* Findings from a study of same-day PrEP initiation among gay men and other men who have sex with men ([link removed])

* Data from the ASCENT study evaluating an HIV mosaic vaccine ([link removed])


For the full conference program (www.ias2019.org/Programme) go to the website for IAS 2019, and find your optimal schedule for following HIV prevention research with AVAC’s conference roadmap, which can be sorted by timing, intervention or session type:

Excel: www.avac.org/sites/default/files/u3/IAS2019_roadmap.xlsx
PDF: www.avac.org/sites/default/files/u3/IAS2019_roadmap.pdf

Consider adding these satellite and conference events below, some hosted by AVAC and partners, to your calendar!

------------------------------------------------------------

“Sticky Linkage”: Latest evidence and new strategies ([link removed])
Sunday 21 July, 8:00-10:00, Palacio de Iturbide 1 y 2

This session on approaches for improving ART initiation and retention talks about challenges to the idea that the continuum of care is linear. On the agenda, the results of segmentation research aimed at improving linkage to treatment among South African men.

------------------------------------------------------------

Hormonal contraception and HIV risk: Understanding the ECHO trials results, and what’s next for women, providers, policies, and programmes ([link removed])
Sunday 21 July, 17:00-19:00, Palacio de Valparaíso 2

Come to this forum to hear a review of the ECHO study results and discussion of their implications for women, providers, policies and programs. Presentations will focus on informed choice for women, the need to expand method mix, and the importance of integrating HIV prevention with sexual and reproductive health.

------------------------------------------------------------

An HIV vaccine to prevent HIV acquisition ([link removed])
Sunday 21 July, 17:00-19:00, Palacio de Valparaíso 1

Learn more about the newest candidate for a vaccine to be investigated in a trial known as Mosaico. This session will provide an overview of pre-clinical work and next steps for the latest mosaic vaccine strategy.

------------------------------------------------------------

New data from six locations inform the future of the HIV response ([link removed])
Monday 22 July, 14:15-15:00

This press conference will unveil a new analysis from AVAC, amfAR and Friends of the Global Fight of six case studies of progress toward epidemic control. From the report Translating Progress Into Success to End the AIDS Epidemic, the analysis identifies elements that accelerate the impact of treatment and prevention with implications for program, policy, implementation and advocacy. The press conference will only be open to journalists, but you can watch the livestream ([link removed]).

------------------------------------------------------------

Improving prevention choice, while we wait for an HIV vaccine: Prioritizing resources for key population-specific prevention research and implementation ([link removed])
Tuesday 23 July, 14:30-16:00, Palacio de Valparaíso 1

For a broad analysis of improving prevention for key populations, check out this presentation, part of a larger session titled, Prevention is more than PrEP ([link removed]).

------------------------------------------------------------

High adherence and sustained impact on HIV-1 incidence: Final results of an open-label extension trial of the dapivirine vaginal ring ([link removed])
Tuesday 23 July, 14:30-16:00, Palacio de Valparaíso 2

Catch the latest results on the effectiveness of the dapivirine vaginal ring at this session on the findings of the HOPE open-label study (www.avac.org/trial/mtn-025-hope).


Following from afar?

AVAC will offer comments and updates on Twitter (twitter.com/HIVpxresearch) and Facebook (facebook.com/HIVpxresearch/). Use the conference hashtag — #IAS2019.

Get the latest news on the conference at this dedicated page on the IAS 2019 website (www.ias2019.org/Media-Centre/News).

And watch this space for additional updates.

Best,
AVAC

============================================================
Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe

Contact Us T: +1 212 796 6423
E: ** [email protected]
W: ** www.avac.org
** www.twitter.com/hivpxresearch
** www.facebook.com/hivpxresearch
** www.youtube.com/hivpxresearch
==============================================

Unsubscribe [email protected] from this list:
[link removed]